We previously reported that 17,8-estradiol inhibits cytokinestimulated bioassayable IL-6 and the steady-state level of IL-6 mRNA. To determine the molecular basis of this effect, the transient expression of chloramphenicol acetyltransferase (CAT) reporter plasmid driven by the human IL-6 promoter was studied here in HeLa or murine bone marrow stromal cells (MBA 13.2). 1713-estradiol (10-8 M) completely suppressed stimulated CAT expression in HeLa cells cotransfected with IL-6/CAT constructs and a human estrogen receptor (hER) expression plasmid; but had no effect on reporter expression in HeLa cells not transfected with hER. 17fl-estradiol also inhibited stimulated expression in MBA 13.2 cells (which express the estrogen receptor constitutively) without the requirement of cotransfection of the hER plasmid. The hormonal effects were indistinguishable between constructs containing a 1.2-kb fragment of the 5' flanking region of the IL-6 gene or only the proximal 225-bp fragment. However, yeast-derived recombinant hER did not bind to the 225-bp segment in DNA band shift assays, nor did the 225-bp fragment compete for binding of an estrogen response element oligonucleotide to yeast-derived estrogen receptor. These data suggest that 17,6-estradiol inhibits the stimulated expression of the human IL-6 gene through an estrogen receptor mediated indirect effect on the transcriptional activity of the proximal 225-bp sequence of the promoter. (J. Clin. Invest. 1994. 93:944-950.)
Introduction IL-6 plays an important role in the replication and differentiation of hematopoietic cell precursors including the colonyforming units/granulocytes/macrophages (1) (2) (3) , which are the presumed progenitors of the bone resorbing osteoclasts (4, 5) . Moreover, deregulated production ofIL-6 might be responsible for increased osteoclastogenesis in pathologic states associated with increased bone resorption, such as multiple myeloma (6) and Paget's disease (7) .
Results from previous in vitro (8) as well as in vivo studies (9) of ours have also suggested a link between 17,B-estradiol, , and the bone loss that is associated with loss of ovarian function. Specifically, we have found that IL-6 is produced by murine bone marrow-derived stromal cell lines, normal hu-man bone-derived cells, and nontransformed osteoblast cell lines from mice and rats. In all these cell types, IL-6 production was stimulated in response to the combination of IL-1 and TNF. Addition of 1 7f-estradiol into these cultures caused inhibition of IL-1-and/or TNF-induced production of bioassayable IL-6 and the levels of the IL-6 mRNA. Based on these in vitro findings, we proceeded to test in vivo the hypothesis that estrogen loss upregulates osteoclastogenesis through an increase in the production of IL-6 in the microenvironment of the marrow. In support ofthis hypothesis, we found that loss of estrogens (ovariectomy) in mice caused upregulation of the formation of colony-forming units/granulocytes/macrophages colonies in short-term cultures of marrow cells from ovariectomized animals. Similarly, marrow cell cultures from ovariectomized mice exhibited consistently greater numbers of osteoclasts. Furthermore, we found that ovariectomy causes a significant increase in the number of osteoclasts present in sections of trabecular bone. All these changes could be prevented by a neutralizing antibody against IL-6, as well as by estrogen replacement, indicating a mediating role of IL-6 in the upregulated osteoclastogenesis, which ensues upon estrogen deficiency (9) .
In the studies presented here, we have investigated the molecular basis of the inhibiting effect of 173-estradiol on IL-6 production. To do this, we have used HeLa cells, a well-established cell model ofinduced IL-6 transcription by both phorbol esters and cytokines (10) , as well as the murine bone marrow stromal cell line MBA 13 .2, which, as we have shown earlier (8) , expresses the IL-6 gene. We present evidence that 171-estradiol, acting via its receptor, inhibits the stimulated expression of human IL-6 promoter-reporter constructs in both cell lines. However, this effect does not appear to be mediated by direct interaction ofthe human estrogen receptor with the IL-6 promoter.
Methods
Chemicals and reagents. 17fl-estradiol, 1 7a-estradiol, progesterone, Construction of reporter plasmids. The IL-6 promoter was amplified using human genomic DNA as the template. The upstream primer extended from bp -1,183 to -1,160 and contained a native restriction site for BamHI at bp -1,179. The downstream oligonucleotide was complementary to bp +9 through +31 of the IL-6 gene and contained an engineered restriction site for KpnI at bp +26. Conditions used for the amplification of this region of the IL-6 promoter were 1 min at 940C, 1 min at 60'C, and 2 min at 720C for 30 cycles. The amplified product was electrophoresed on a 1% agarose gel. A discrete band of expected size 1.2 kb was isolated from the gel, digested with BamHI and KpnI, and subsequently cloned into pUCAT-I to generate pIL-6/CAT I (Fig. 1) . Confirmation of the insert's identity with the known sequence of the promoter was obtained by restriction mapping and sequencing using the chain termination method. To construct pIL-6/ CAT 2, pIL-6/CAT 1 was digested with BamHI and NheI, the ends were filled in with Klenow fragment of DNA polymerase to create blunt ends and then religated.
Cells and culture conditions. HeLa cells were obtained from American Type Culture Collection (Rockville, MD) and maintained in phenol red-free DME supplemented with 5% FCS. The MBA 13.2 bone marrow-derived murine stromal cell line ( 13) was provided by Dr. Zipori from the Weismann Institute (Rehovot, Israel) and were maintained in phenol red-free McCoy's 5A (Sigma Chemical Co.) medium supplemented with 10% FBS (Hyclone Laboratories, Logan, UT), penicillin (100 U/ml), and streptomycin (100 pg/ml) at 37C in 5% CO2 in air. 1 7fl-Estradiol binding studies. The concentration of 1 7,B-estradiol receptor sites in HeLa cells transfected with the hER expression plasmid or wild-type HeLa cells transfected with the vector alone was assayed using 1251_1713-estradiol and a previously described method ( 14) with slight modifications. Briefly, 40 h after transfection cells were harvested by trypsinization and washed twice in PBS ( 120 mM NaCl, 2.7 mM KC1, 10 mM sodium phosphate pH 7. Assay ofreporter genes. CAT enzyme activity in cell extracts was determined after heat treatment (60°C for 10 min) to inactivate cellular deacetylation activity, as described earlier ( 17) 
Results
Before determining the effect of 1 73-estradiol on the IL-6 promoter activity, the level ofthe 1 7f-estradiol receptor expressed by the cells used in these experiments was determined by means of 12511. 17 ( 19) .
The results of a representative experiment examining the effect of 17,B-estradiol on the activity of the IL-6/CAT 1 plasmid are illustrated in Fig. 3 A. CAT activity was very low in unstimulated HeLa cells transfected with the IL-6 /CAT 1 plasmid ( lanes 3 and 4) ; however, stimulation of the cells with PMA caused a marked increase in CAT activity (lanes 5 and 6). Cotransfection ofthe cells with the hER expression plasmid had no discernable effect on the PMA-stimulated CAT activity. Similarly, pretreatment with 1 73-estradiol (10-8 M) of cells transfected only with the IL-6/CAT 1 had no effect on the activity ofthe reporter enzyme (lanes 7-9). However, pretreatment with 1 7f3-estradiol ofcells transfected both with the IL-6 / CAT 1 plasmid and the hER expression plasmid completely prevented the PMA-induced stimulation of CAT activity (lanes IO and II). Similar results to those shown in Fig. 3 A were obtained in five additional experiments, the results of which are summarized in Fig. 3 Figure 4 . 17f3-estradiol inhibits stimulated transcription from the proximal 225 bp of the human IL-6 promoter in transfected HeLa cells. HeLa cells were transfected with the IL-6/CAT 2 construct alone or with both the IL-6/CAT 2 and an hER expression plasmid, using the calcium phosphate precipitation method. After transfection, the cells were incubated as in Fig. 3 (Fig. 7) . This effect was completely inhibited by preincuheir respective affinities for bation of the MBA 13.2 cells with 1 7f-estradiol. Finally, to investigate whether the ER-mediated effect of 1 7f-estradiol was caused by direct interaction of the receptor ke the evidence from the ligand complex with the IL-6 promoter sequence, we studied demonstration th c fomithe the ability ofthe 225-bp fragment to compete for binding ofthe demonstration of constituyeast-derived hER to a labeled ERE. As shown in Fig. 8 (Fig.  8) . Gel retardation assays were also performed using the 225-bp fragment as the labeled probe (Fig. 9) 3) . Addition of E2 completely eliminated the PMA-induced increase in CAT activity (lanes 6 and 7).
Discussion
The expression of the pleiotropic cytokine IL-6 is regulated by many agents, including phorbol esters (PMA), cytokines such as IL-1 and TNF (20) (10,M) . parathyroid hormone and the parathyroid hormone related peptide (21) . Although the expression of IL-6 is tightly controlled, upregulation of its production is now recognized to play a critical role in the pathogenesis of several disease states (6, 7) .
The data presented in this paper represent an extension of our earlier observations that cytokine-stimulated IL-6 production by bone marrow and bone-derived cells from rodents and humans is inhibited by 1 7f-estradiol (8) . Specifically, the present results establish that 1 7/3-estradiol inhibits IL-6 production through a potent effect of the hormone on the activity of the IL-6 promoter in transfection assays. The demonstration of this effect using the human IL-6 promoter-reporter constructs in human cells (HeLa) indicates that the molecular mechanism elucidated in our studies is relevant to human biology. In addition, the confirmation of the findings in a bone marrowderived cell line indicates that these observations are relevant to the role of IL-6 in bone homeostasis. Furthermore, taken together with the in vivo evidence for the mediating role ofIL-6 in the osteoclastogenesis that ensues upon ovariectomy in mice (9), the observations ofthis paper strongly support the contention that the regulation of IL-6 by 1 7f3-estradiol is indeed relevant to the bone changes associated with the loss of ovarian function in humans. The 1.2-kb fragment of the 5' flanking region of the IL-6 gene contains three transcription start sites and all the necessary elements for induction of the IL-6 gene by a variety of stimuli (22) . Deletion analysis previously performed by others indicates that the proximal 225-bp segment of the promoter is involved in the inducibility of the IL-6 gene by phorbol esters and cytokines in transient transfection assays in HeLa cells (10) . Based on this evidence, we have examined the effect of Figure 8 . ER In these experiments, we were unable to demonstrate a direct interaction between the estrogen receptor and the human IL-6 promoter. This is consistent with the fact that the proximal 225 bp of the IL-6 promoter, which drives transcription of the IL-6/CAT 2 construct, lacks a classical estrogen response element. Therefore, the inhibition of expression of IL-6 promoter-CAT fusion genes by the activated ER appears to be exerted indirectly through an as yet unknown mechanism, perhaps by influencing transcriptional factors generated in response to the agents that stimulate IL-6 production or through effects on other events along the signaling pathway.
An alternative mechanistic explanation ofthe results ofour studies is that the hER interacts directly (protein-protein) with other trans activators involved in IL-6 gene regulation. A precedent for such a mechanism of action for a steroid hormone is established in the case of the interaction between the glucocorticoid receptor and the transcriptional factor AP-1, a heterodimer ofthe oncogene products c-fos and c-jun. Indeed, inhibition of basal and induced transcription ofthe collagenase gene by glucocorticosteroids is exerted through interference with the action of AP-1 (23, 24) . The possibility that the hER can interfere with AP-I or other transcription factor activity through protein-protein interactions will also require further studies.
In conclusion, the results presented here indicate that 173-estradiol inhibits IL-6 production via a receptor-mediated action that results in the inhibition of expression of a reporter construct driven by the IL-6 promoter. It seems likely, but is yet unproven, that this effect occurs at the level of gene transcription. However, this effect does not appear to be mediated by direct interaction of the hER with the IL-6 promoter, but perhaps through an interference with events along the signaling pathways initiated by the IL-6-stimulating agents.
